Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan-Feb;15(1):295-301.
doi: 10.1016/j.dsx.2020.12.040. Epub 2021 Jan 13.

Potential beneficial role of probiotics on the outcome of COVID-19 patients: An evolving perspective

Luigi Santacroce  1 , Francesco Inchingolo  2 , Skender Topi  3 , Raffaele Del Prete  4 , Michele Di Cosola  5 , Ioannis Alexandros Charitos  6 , Monica Montagnani  7
Affiliations
Review

Potential beneficial role of probiotics on the outcome of COVID-19 patients: An evolving perspective

Luigi Santacroce et al. Diabetes Metab Syndr. 2021 Jan-Feb.

Abstract

Background and aims: Probiotics can support the body's systems in fighting viral infections. This review is aimed to focus current knowledge about the use of probiotics as adjuvant therapy for COVID-19 patients.

Methods: We performed an extensive research using the PubMed-LitCovid, Cochrane Library, Embase databases, and conducting manual searches on Google Scholar, Elsevier Connect, Web of Science about this issue.

Results: We have found several papers reporting data about the potential role of probiotics as well as contrasting experimental data about it.

Conclusions: Most data show good results demonstrating that probiotics can play a significant role in fighting SARS-CoV-2 infection, also compared with their use in the past for various diseases. They seem effective in lowering inflammatory status, moreover in patients with chronic comorbidities such as cancer and diabetes, improving clinical outcomes.

Keywords: Dysbiosis; Human microbiota; Pharmacological effects; Probiotics; SARS-Cov-2.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Gut/Lung axis: the hypothesis that the intestinal microbiota can modulate the immunological activity of the lung and vice versa: Lipopolysaccharides (LPSs) promote the activation of nuclear factor kappa-light chain-enhancer (NFkb) and plasma cells with various T cells, in particular regulatory T or suppressor T cells (Treg cells), T helper 17 (T-h17), T helper 1 (Th1) migrating later to the lung through the bloodstream. The bacterial metabolites, in particular short chain fatty acids (SCFAs) act directly on the nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB), reducing production of tumor necrosis factor alpha (TNF-α) and the downregulation of the pattern recognition receptors (PRRs). This will lead to the reduction of the inflammatory cytokines and lung immunomodulation. Then, interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), interferon gamma (IFNγ) and lymphocytes migrate to the gut .
Fig. 2
Fig. 2
The “immunity dysregulation dysbiosis cycle” (IDDC) hypothesis in SARS-CoV-2 patients: in the context of SARS-Cov-2 infection, it is important to consider the patient’s age, comorbidities, malnutrition, superinfections, antibiotics and antivirals which could result in further microbiota dysbiosis. This will lead to direct dysregulation of the human microbiota and of the intestinal, pulmonary, brain and skin axes. Consequently, immune dysregulation will increase leading to continuous increased microbiota dysbiosis and immune dysregulation. All this can contribute to a severe prognosis for the patients.
Fig. 3
Fig. 3
The various bacteria strains with the two different action ability. In general, probiotics can (a) compete with pathogens for sites of attachment to the mucosa; (b) modulate and strengthen the expression of genes that code for the proteins of the junctions themselves; (c) produce low molecular weight organic acids (lactic acid and acetic acid) and bacteriocins (proteinaceous or peptidic toxins for some pathogenic bacteria) and (d) modulate the immune system for the benefit of the persons or patients, mainly through the increase of antibodies level and inhibitory effects on inflammatory interleukins.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Update on COVID-19 and Effectiveness of a Vaccination Campaign in a Global Context.
    Charitos IA, Ballini A, Lovero R, Castellaneta F, Colella M, Scacco S, Cantore S, Arrigoni R, Mastrangelo F, Dioguardi M. Charitos IA, et al. Int J Environ Res Public Health. 2022 Aug 28;19(17):10712. doi: 10.3390/ijerph191710712. Int J Environ Res Public Health. 2022. PMID: 36078427 Free PMC article. Review.
  • Oral booster probiotic bifidobacteria in SARS-COV-2 patients.
    Bozkurt HS, Bilen Ö. Bozkurt HS, et al. Int J Immunopathol Pharmacol. 2021 Jan-Dec;35:20587384211059677. doi: 10.1177/20587384211059677. Int J Immunopathol Pharmacol. 2021. PMID: 34818923 Free PMC article.
  • Oral microbiota in human health and disease: A perspective.
    Santacroce L, Passarelli PC, Azzolino D, Bottalico L, Charitos IA, Cazzolla AP, Colella M, Topi S, Godoy FG, D'Addona A. Santacroce L, et al. Exp Biol Med (Maywood). 2023 Aug;248(15):1288-1301. doi: 10.1177/15353702231187645. Epub 2023 Sep 9. Exp Biol Med (Maywood). 2023. PMID: 37688509 Free PMC article. Review.
  • Effectiveness of SARS-CoV-2 Vaccines for Short- and Long-Term Immunity: A General Overview for the Pandemic Contrast.
    Inchingolo AD, Malcangi G, Ceci S, Patano A, Corriero A, Vimercati L, Azzollini D, Marinelli G, Coloccia G, Piras F, Barile G, Settanni V, Mancini A, De Leonardis N, Garofoli G, Palmieri G, Isacco CG, Rapone B, Scardapane A, Curatoli L, Quaranta N, Ribezzi M, Massaro M, Jones M, Bordea IR, Tartaglia GM, Scarano A, Lorusso F, Macchia L, Larocca AMV, Aityan SK, Tafuri S, Stefanizzi P, Migliore G, Brienza N, Dipalma G, Favia G, Inchingolo F. Inchingolo AD, et al. Int J Mol Sci. 2022 Jul 30;23(15):8485. doi: 10.3390/ijms23158485. Int J Mol Sci. 2022. PMID: 35955621 Free PMC article. Review.
  • Current Views About the Link between SARS-CoV-2 and the Liver: Friends or Foe?
    Lovero R, Charitos IA, Topi S, Castellaneta F, Cazzolla AP, Colella M. Lovero R, et al. Endocr Metab Immune Disord Drug Targets. 2024;24(6):642-650. doi: 10.2174/0118715303251985231009050626. Endocr Metab Immune Disord Drug Targets. 2024. PMID: 37846575
See all "Cited by" articles

References

    1. Ursell L.K., Metcalf J.L., Parfrey L.W., Knight R. Defining the human microbiome. Nutr Rev. 2012;70(1):S38–S44. doi: 10.1111/j.1753-4887.2012.00493.x. - DOI - PMC - PubMed
    1. Sender R., Fuchs S., Milo R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 2016 Aug 19;14(8) doi: 10.1371/journal.pbio.1002533. - DOI - PMC - PubMed
    1. Human Microbiome Project Consortium Structure, function and diversity of the healthy human microbiome. Nature. 2012;486(7402):207–214. doi: 10.1038/nature11234. - DOI - PMC - PubMed
    1. Bottalico L., Castellaneta F., Charitos I.A. From hydrotherapy to the discovery of the gut microbiota: the historical gastrointestinal health concept. Pharmacophore. 2020;11(2):82–90.
    1. Ballini A., Dipalma G., Isacco C.G., Boccellino M., Di Domenico M., Santacroce L. Oral microbiota and immune system crosstalk: a translational research. Biology (Basel) 2020;9(6):131. doi: 10.3390/biology9060131. - DOI - PMC - PubMed

MeSH terms